Non-Hodgkin's lymphomas constitute a highly heterogeneous group of neoplasms. Their origin lies in the lymphatic cells of our immune system. Despite their biological variance, they can be clinically classified into indolent and aggressive lymphomas. This categorization has prognostic and therapeutic implications. The goal of treatment in aggressive lymphoma is full remission, which usually requires an intensive treatment regimen. In cases of indolent lymphoma, cure is not the therapeutic goal, but rather disease control. Recent developments have led to novel therapeutic options in addition to the classic well-known chemotherapies and anti-CD20 antibodies. The use of a variety of targeted therapies, including cellular therapies such as chimeric antigen receptor (CAR) T cells, has led to significantly improved outcomes.